IL163808A0 - Self emulsifying drug delivery systems for poorly soluble drugs - Google Patents

Self emulsifying drug delivery systems for poorly soluble drugs

Info

Publication number
IL163808A0
IL163808A0 IL16380803A IL16380803A IL163808A0 IL 163808 A0 IL163808 A0 IL 163808A0 IL 16380803 A IL16380803 A IL 16380803A IL 16380803 A IL16380803 A IL 16380803A IL 163808 A0 IL163808 A0 IL 163808A0
Authority
IL
Israel
Prior art keywords
drug delivery
delivery systems
poorly soluble
soluble drugs
emulsifying drug
Prior art date
Application number
IL16380803A
Other languages
English (en)
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02290513A external-priority patent/EP1340497A1/en
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of IL163808A0 publication Critical patent/IL163808A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cash Registers Or Receiving Machines (AREA)
IL16380803A 2002-03-01 2003-02-28 Self emulsifying drug delivery systems for poorly soluble drugs IL163808A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36109002P 2002-03-01 2002-03-01
EP02290513A EP1340497A1 (en) 2002-03-01 2002-03-01 Self emulsifying drug delivery systems for poorly soluble drugs
PCT/IB2003/001336 WO2003074027A2 (en) 2002-03-01 2003-02-28 Self emulsifying drug delivery systems for poorly soluble drugs

Publications (1)

Publication Number Publication Date
IL163808A0 true IL163808A0 (en) 2005-12-18

Family

ID=27790109

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16380803A IL163808A0 (en) 2002-03-01 2003-02-28 Self emulsifying drug delivery systems for poorly soluble drugs

Country Status (10)

Country Link
US (1) US20050232952A1 (https=)
EP (1) EP1480636B1 (https=)
JP (1) JP2005523295A (https=)
AT (1) ATE359779T1 (https=)
AU (1) AU2003214538A1 (https=)
CA (1) CA2478424A1 (https=)
DE (1) DE60313299T2 (https=)
ES (1) ES2283756T3 (https=)
IL (1) IL163808A0 (https=)
WO (1) WO2003074027A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163726B2 (en) 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
WO2008042841A2 (en) * 2006-10-02 2008-04-10 Dr. Reddy's Laboratories Limited Docetaxel compositions
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
CA2686225A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
EP2178893A4 (en) * 2007-07-16 2012-09-19 Poniard Pharmaceuticals Inc ORAL FORMULATIONS FOR PICOPLATIN
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
JP2011516472A (ja) * 2008-04-04 2011-05-26 ショール，ロバート 微小管相互作用薬の脂質−油−水型ナノエマルジョンデリバリシステム
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
JP5868414B2 (ja) 2010-11-08 2016-02-24 カディラ ファーマシューティカルズ リミテッド タキソイドの医薬組成物
WO2013180253A1 (ja) * 2012-05-31 2013-12-05 テルモ株式会社 ｐＨ感受性担体およびその製造方法、並びに該担体を含むｐＨ感受性医薬、ｐＨ感受性医薬組成物およびこれを用いた培養方法
EP3424493A1 (en) 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
CN109589305B (zh) * 2018-12-03 2021-03-19 昆明积大制药股份有限公司 多西他赛-环孢素a共包载自乳化制剂及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656779B1 (en) * 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5627209A (en) * 1993-12-15 1997-05-06 Alcon Laboratories, Inc. Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
US5567424A (en) * 1994-06-10 1996-10-22 Reliv International, Inc. Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption
US5536516A (en) * 1994-08-24 1996-07-16 Renaissance Herbs, Inc. Hydroxycitric acid concentrate and food products prepared therefrom
WO1996036585A1 (en) * 1995-05-15 1996-11-21 Sabinsa Corporation A new process for the production of potassium hydroxy citric acid, and compositions containing the potassium hydroxy citric acid
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
IT1276253B1 (it) * 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
US5716976A (en) * 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US6160172A (en) * 1997-08-27 2000-12-12 Vittal Mallya Scientific Research Foundation Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
AU5802499A (en) * 1998-09-01 2000-03-21 Amway Corporation Diet composition and method of weight management
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6207714B1 (en) * 1999-09-14 2001-03-27 Dallas L. Clouatre Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid
US6447807B1 (en) * 1999-09-14 2002-09-10 Dallas L. Clouatre Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6399089B1 (en) * 2000-05-15 2002-06-04 A. Glenn Braswell Compositions and methods for regulating metabolism and balancing body weight
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US6579866B2 (en) * 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US20040157929A1 (en) * 2002-04-01 2004-08-12 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
US6476071B1 (en) * 2001-05-07 2002-11-05 Dallas L. Clouatre Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid
US6441041B1 (en) * 2001-06-20 2002-08-27 Dallas L. Clouatre (-)-hydroxycitric acid for the prevention of osteoporosis
US6482858B1 (en) * 2001-06-20 2002-11-19 Dallas L Clouatre (−)-hydroxycitric acid for wound healing and immunomodulation
US6638542B2 (en) * 2001-09-20 2003-10-28 Nutricia N.V. Reducing appetite in mammals by administering procyanidin and hydroxycitric acid
US7119110B2 (en) * 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US20030119913A1 (en) * 2001-12-20 2003-06-26 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
US7507421B2 (en) * 2002-04-30 2009-03-24 Unibar Corporation Hydroxycitric acid salt composition and method of making
TW200427447A (en) * 2003-03-21 2004-12-16 Interhealth Nutraceuticals Inc Method and composition for decreasing ghrelin levels

Also Published As

Publication number Publication date
AU2003214538A1 (en) 2003-09-16
EP1480636A2 (en) 2004-12-01
US20050232952A1 (en) 2005-10-20
EP1480636B1 (en) 2007-04-18
ES2283756T3 (es) 2007-11-01
DE60313299D1 (de) 2007-05-31
CA2478424A1 (en) 2003-09-12
WO2003074027A3 (en) 2003-12-18
DE60313299T2 (de) 2008-01-03
WO2003074027A2 (en) 2003-09-12
WO2003074027A8 (en) 2004-10-07
ATE359779T1 (de) 2007-05-15
JP2005523295A (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
IL163808A0 (en) Self emulsifying drug delivery systems for poorly soluble drugs
WO2005020962A8 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
WO2000074661A3 (en) Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
WO2002007712A3 (en) Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
MX2012014443A (es) Composiciones oftalmicas para la administracion de ingredientes activos liposolubles.
CO5580835A2 (es) Nuevas formulaciones analogas de ciclosporina
US20190374508A1 (en) Therapeutic topical compositions of apremilast
Rodriguez et al. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
SI1521572T1 (sl) Film, ki se da bioerodirati, za dajanje oftalmičnega zdravila
AU2011327824B2 (en) Pharmaceutical composition of taxoids
WO2005087195A3 (en) Novel compositions for topical delivery
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
US20240390380A1 (en) Laureth-4 containing topical formulations
ATE541562T1 (de) Ibuprofen-suspension
DE69920201D1 (de) Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d
HRP20090418T1 (hr) Farmaceutski pripravak koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
SG146638A1 (en) Pharmaceutical delivery system
BR0215187A (pt) Composições farmacêuticas que compreendem uma ciclosporina, um tensoativo hidrofìlico e um tensoativo lipofìlico
DE69924004D1 (de) Verabreichungssystem für wasserunlösliche arzneistoffe
WO2005020959A3 (en) Novel drug compositions and dosage forms of topiramate
WO2006060325A3 (en) Coated drug delivery formulations
IL173847A (en) Pharmaceutical composition in a form of anhydrous self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
CA2866795C (en) Paralytic shellfish poison for use in topical treatment of itching